Hereditary nonpolyposis colorectal cancer secondary prevention: Difference between revisions
No edit summary |
No edit summary |
||
Line 11: | Line 11: | ||
Recent studies demonstrate a reduced [[incidence]] in [[hereditary nonpolyposis colorectal cancer]] [[Patient|patients]] who were exposed to at least four years of high-dose [[aspirin]], with a satisfactory risk profile. These results have been widely covered in the media; future studies will look at modifying (lowering) the dose (to reduce risk associated with the high dosage of ASA). | Recent studies demonstrate a reduced [[incidence]] in [[hereditary nonpolyposis colorectal cancer]] [[Patient|patients]] who were exposed to at least four years of high-dose [[aspirin]], with a satisfactory risk profile. These results have been widely covered in the media; future studies will look at modifying (lowering) the dose (to reduce risk associated with the high dosage of ASA). | ||
[[Secondary prevention]] strategies following [[hereditary nonpolyposis colorectal cancer]] include:<ref name="hnpcc">Kladny J, Lubinski J. Lynch syndrome (HNPCC). Hered Cancer Clin Pract. 2008;6(2):99-102.</ref> | [[Secondary prevention]] strategies following [[hereditary nonpolyposis colorectal cancer]] include:<ref name="hnpcc">Kladny J, Lubinski J. Lynch syndrome (HNPCC). Hered Cancer Clin Pract. 2008;6(2):99-102.</ref><ref name="pmid19659756">{{cite journal| author=Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR| title=Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. | journal=Clin Genet | year= 2009 | volume= 76 | issue= 1 | pages= 1-18 | pmid=19659756 | doi=10.1111/j.1399-0004.2009.01230.x | pmc=2846640 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19659756 }} </ref><ref name="pmid8612988">{{cite journal| author=Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G et al.| title=Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. | journal=Gastroenterology | year= 1996 | volume= 110 | issue= 4 | pages= 1020-7 | pmid=8612988 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8612988 }} </ref> | ||
* [[Colonoscopy]] between 25-35 years, every 2 years. | * [[Colonoscopy]] between 25-35 years, every 2 years. |
Revision as of 06:04, 11 February 2019
Hereditary Nonpolyposis Colorectal Cancer Microchapters |
Differentiating Hereditary Nonpolyposis Colorectal Cancer from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hereditary nonpolyposis colorectal cancer secondary prevention On the Web |
American Roentgen Ray Society Images of Hereditary nonpolyposis colorectal cancer secondary prevention |
FDA on Hereditary nonpolyposis colorectal cancer secondary prevention |
CDC on Hereditary nonpolyposis colorectal cancer secondary prevention |
Hereditary nonpolyposis colorectal cancer secondary prevention in the news |
Blogs on Hereditary nonpolyposis colorectal cancer secondary prevention |
Directions to Hospitals Treating Hereditary nonpolyposis colorectal cancer |
Risk calculators and risk factors for Hereditary nonpolyposis colorectal cancer secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Overview
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include genetic testing, colonoscopy, urine cytology, pelvic exam and endometrial biopsy.
Secondary prevention
Recent studies demonstrate a reduced incidence in hereditary nonpolyposis colorectal cancer patients who were exposed to at least four years of high-dose aspirin, with a satisfactory risk profile. These results have been widely covered in the media; future studies will look at modifying (lowering) the dose (to reduce risk associated with the high dosage of ASA).
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include:[1][2][3]
- Colonoscopy between 25-35 years, every 2 years.
- Pelvic exam, transvaginal ultrasound and CA-125 between 25-35 years, every year.
- Endometrial biopsy, in relation to clinical symptoms.
- Urine cytology (families who have someone diagnosed with transitional cell carcinoma of the ureter or renal pelvis, between 25-35 years every year)
References
- ↑ Kladny J, Lubinski J. Lynch syndrome (HNPCC). Hered Cancer Clin Pract. 2008;6(2):99-102.
- ↑ Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR (2009). "Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications". Clin Genet. 76 (1): 1–18. doi:10.1111/j.1399-0004.2009.01230.x. PMC 2846640. PMID 19659756.
- ↑ Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G; et al. (1996). "Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis". Gastroenterology. 110 (4): 1020–7. PMID 8612988.